Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00334776 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00334776 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma |
| Lead sponsor | University of Southern California, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide |
| Enrollment | 6 |
| Start date | Oct 1, 2003 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jun 8, 2006 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: